Search
Research
The cost-of-illness due to rheumatic heart disease: national estimates for FijiWe estimate for the first time the total cost of RHD for Fiji (2008-2012) using a cost-of-illness approach and novel primary data on RHD disease burden and costs.
Research
Low positive predictive value of International Classification of Diseases, 10th Revision codes in relation to rheumatic heart disease: a challenge for global surveillanceWe outline a series of research initiatives to improve identification of RHD in administrative data thereby contributing to monitoring the RHD burden globally
Research
Establishing a Western Australian Congenital and Acquired Heart Disease DatabaseThe main objective of the study is to establish a comprehensive register of congenital and acquired heart disease in WA with accurate re-classification of all cases through Princess Margart Hospital using international diagnostic codes.
Research
Evaluating the genetic contribution to rheumatic heart disease pathogenesis in Australian Aboriginal and Torres Strait Islander communitiesWe are conducting a genetic study to better understand why some people are susceptible to RHD and others are not.
Research
Head-to-head Pharmacokinetic Comparison of Bicillin ® L-A versus Lyophilised (Powdered) Benzathine Penicillin G administered by the Intramuscular and Subcutaneous RoutesFiji has one of the highest burdens of RHD is in the world and RHD is the second most common cause of death in young people in Fiji.
Research
Pacific Rheumatic Heart Disease (RHD) ProgramThe goal of the program is to establish the foundations of an effective, sustainable and equitable response to RHD in the Pacific.
Research
The evidence that rheumatic heart disease control programs in Australia are making an impactRheumatic heart disease (RHD) comprises heart-valve damage caused by acute rheumatic fever (ARF). The Australian Government Rheumatic Fever Strategy funds RHD Control Programs to support detection and management of ARF and RHD. We assessed epidemiological changes during the years of RHD Control Program operation.
Research
Roadmap to incorporating group A Streptococcus molecular point-of-care testing for remote Australia: a key activity to eliminate rheumatic heart diseaseJonathan Asha Dylan Rosemary Janessa Jeffrey Carapetis AM Bowen Barth Wyber Pickering Cannon AM MBBS FRACP FAFPHM PhD FAHMS BA MBBS DCH FRACP PhD
Research
Left ventricular remodelling in rheumatic heart disease – trends over time and implications for follow-up in childhoodRheumatic heart disease (RHD) is the most common form of acquired heart disease worldwide. In RHD, volume loading from mitral regurgitation leads to left ventricular (LV) dilatation, increased wall stress, and ultimately LV dysfunction. Improved understanding of LV dynamics may contribute to refined timing of intervention.
Research
Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart diseaseRegular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months.